We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Biologic Indian detour adds value.
- Authors
Jayaraman, Killugudi
- Abstract
The article discusses the added value in a drug sold by an Indian company that was originally developed in the West. It cites the licensing deal of Sanofi at 613 million U.S. dollars (USD) with Indian drug maker Glenmark for a new anti-inflammatory monoclonal body (mAb) called GBR 500 bought by the Mumbai company for 1 million USD from Chromos Molecular systems of Vancouver. It also notes the investment of Glenmark of 17 million USD for developing GBR 500 as treatment for multiple sclerosis while Sanofi paid 50 million USD to develop GBR 500.
- Subjects
SANOFI-Aventis SA; PHARMACEUTICAL industry; ANTI-inflammatory agents; MONOCLONAL antibodies; MULTIPLE sclerosis
- Publication
Nature Biotechnology, 2011, Vol 29, Issue 7, p561
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0711-561c